JAK
Los inhibidores de la Janus quinasa (JAK) son compuestos que se dirigen a la vía de señalización JAK-STAT, la cual está involucrada en el crecimiento celular, la respuesta inmunitaria y la angiogénesis. Al inhibir JAK, estos compuestos pueden reducir la señalización que conduce a la formación de nuevos vasos sanguíneos en los tumores, inhibiendo así el crecimiento tumoral. Los inhibidores de JAK son importantes en el tratamiento del cáncer y las enfermedades inflamatorias. En CymitQuimica, ofrecemos una amplia gama de inhibidores de JAK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 245 productos de "JAK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidJAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Forma y color:Odour SolidS-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Fórmula:C17H18N6Pureza:98%Forma y color:SolidPeso molecular:306.37JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OForma y color:SolidPeso molecular:407.401JAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Fórmula:C20H12ClN3OForma y color:SolidPeso molecular:345.79DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Fórmula:C25H38N4O3Forma y color:SolidPeso molecular:442.59Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Forma y color:SolidPeso molecular:1514.77SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SForma y color:SolidPeso molecular:873.94HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SForma y color:SolidPeso molecular:1236.36JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SForma y color:SolidPeso molecular:548.67Atinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Fórmula:C16H17FN6O3Pureza:99.36%Forma y color:SolidPeso molecular:360.35Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Fórmula:C32H33F4N9O5Forma y color:SolidPeso molecular:699.66DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Fórmula:C26H35N7O5Forma y color:SolidPeso molecular:525.6Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Fórmula:C20H18FN5O3Pureza:98.05%Forma y color:SolidPeso molecular:395.39WHI-P154
CAS:Fórmula:C16H14BrN3O3Pureza:>98.0%(HPLC)Forma y color:White to Yellow to Orange powder to crystalPeso molecular:376.21WHI-P180 Hydrochloride
CAS:Fórmula:C16H15N3O3·HClPureza:>97.0%(T)(HPLC)Forma y color:White to Light gray to Light yellow powder to crystalPeso molecular:333.77CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Fórmula:C22H19F2N5O2Pureza:99.38%Forma y color:SolidPeso molecular:423.42Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Fórmula:C17H17N7O2SPureza:99.88%Forma y color:SolidPeso molecular:383.43Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.87%Forma y color:SolidPeso molecular:615.61AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Forma y color:Yellow SolidPeso molecular:294.3
